Biogen Inc (BIIB) – Strong operational performance in MS, SMA and Biosimilar Franchises

in on June 11, 2019

Biogen delivered strong financial results during the quarter due to the strong operational performance of the MS, SMA, and biosimilars franchises. Total revenues increased by 11% to $3.5bn and adjusted EPS increased by 15% to $6.98 for Q1FY19.

Number of Pages – 47

Contents

Executive Summary

Financial Statements

–Income Statement and Forecast

–Balance Sheet

–Cash Flow

–Q1FY19 Results – Overview

–Q1FY19 – Product Revenues

–Q1FY19 – R&D Update

–Q1FY19 – Key Developments

–FY19 – Guidance and Conclusion

–GAAP to Non-GAPP Reconciliation

Historical Performance

–Key Ratios

–Profitability Ratios, Asset Turnover Ratio, Growth Ratio

–Per Share Items and Key Ratios

–Key Cash Flow Items

–P/E Band

Product Performance and Key Developments

–Ownership

–Competition

–Key Developments

Valuation and Consensus Performance

–Relative Valuation

–Analyst Recommendations

Market Price Performance

CrispIdea Coverage Chart

Release Information

  • Released
    :

    June 11, 2019

  • Last Updated
    :

    June 27, 2019